ABSTRACT
Objective:To study the safety and efficacy of a treatment protocol using immune checkpoint inhibitors (ICIs) and antiangiogenic targeted drugs (AATDs) in converting 41 patients with initially unresectable to resectable hepatocellular carcinoma (HCC).Methods:The data of 41 patients with initially unresectable HCC treated with immunotherapy combined with targeted therapy from December 2018 to April 2021 in Chinese PLA General Hospital were analysed. There were 34 males and 7 females, aged (51.8±10.7) years. The clinical characteristics, conversion to resectable HCC, adverse drug reactions, surgical data and postoperative complications were analysed. Patients were followed-up by outpatients clinics or telephone calls.Results:There were 5 patients with Chinese Liver Cancer Staging (CNLC)-Ⅰb, 4 with CNLC-Ⅱ, 28 with CNLC-Ⅲa and 4 with CNLC-Ⅲb before the treatment protocol. Among them, 28 patients had portal vein tumor thrombosis (PVTT) and 4 had retroperitoneal lymph node metastases. All patients had a mean tumor diameter of (9.16±4.43) cm before and (6.49±4.69) cm after the treatment protocol. The latter was based on the last assessment before hepatectomy. The efficacy of the treatment protocol in converting unresectable to resectable HCC was assessed by the modified Response Evaluation Criteria in Solid Tumors after 3-15 cycles (median dose cycles, 5) of protocal therapy: 15 patients achieved a complete response; 15 patients achieved a partial response; 6 patients had a stable disease, and 5 patients had a progressive disease. 21 patients (51.2%) experienced adverse reactions associated with drug treatment, which resolved with symptomatic treatment or brief discontinuation of the therapy. All patients underwent successful hepatectomy. Postoperative complications of grade Ⅱ or higher occurred in 9 patients (22.0%). The cumulative overall survival rates at 6 months, 1 year and 2 years from diagnosis were 100.0%, 92.6% and 64.7% respectively. The cumulative overall survival rates at 6 months, 1 year and 2 years after surgery were 95.1%, 74.7% and 60.8%, and the recurrence-free survival rates at 6 months, 1 year and 2 years after surgery were 87.8%, 56.7% and 48.6%, respectively.Conclusions:This study provided preliminary evidences that surgical resection after immunotherapy combined with targeted therapy in patients with initially unresectable HCC was safe and efficacious.
ABSTRACT
Pancreatic cancer is the seventh most common cause of cancer deaths worldwide.Although more and more progress of oncotherapy has been achieved in recent years,very few progress has been achieved in pancreatic cancer.This review summarizes the molecular signaling pathway and relevant targeting drug,their recent clinical and experimental findings of this disease.It also presents the situation and future development of targeting treatment in pancreatic cancer.
ABSTRACT
Purpose:To study the effect of insulin-like growth factor 1 receptor ?-strain(IGF1R-?) interrupted by a special antibody (IGFⅠR-?Mab)on lung adenoma cell line SPC-A-1.Methods:IGFⅠR-?Mab was extracted by hybrid technology. SPC-A-1 cells were separated into 2 groups,the IGFⅠR-?Mab and the blank control. The IGFⅠR-?Mab cells were interfered by different densities of IGFⅠR-?Mab, including 20,40,60,80,100,120,140,160,180 and 200 ng/ml. The MTT curve line, morphology, ultrastructure and cell cycles were observed at 0,24,48,72 hours after the intervention respectively. Results:Compared with the control, apoptosis in IGFⅠR-?Mab group was significant(P= 0.009)and proliferation rate was decreased obviously within 160 ng/ml. However, the proliferation rate was no significant when the special antibody density was more than 200 ng/ml.Conclusions:The affinity of IGFⅠR-?Mab at IGF1R ?-strain is high. The interruption of IGF1R ?-strain by IGFⅠR-?Mab shows the obvious biological effects in vitro ,with inclusion of promoting apoptosis and suppressing proliferation, which indicate the interruption targeting IGF1R ?-strain is prospective for non-small-cell lung carcinoma.
ABSTRACT
0 05); C group compares to B group, P